key: cord-0727010-plt8nj9p
authors: Mai, Huynh Kim; Trieu, Nguyen Bao; Long, Trinh Hoang; Thanh, Hoang Tien; Luong, Nguyen Dinh; Huy, Le Xuan; Nguyet, Lam Anh; Man, Dinh Nguyen Huy; Anderson, Danielle E.; Thanh, Tran Tan; Chau, Nguyen Van Vinh; Thwaites, Guy; Wang, Lin-Fa; Van Tan, Le; Hung, Do Thai
title: Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam
date: 2021-02-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2702.204226
sha: 7736ddbebad0b41ae936fef5267592a2e117a105
doc_id: 727010
cord_uid: plt8nj9p

Antibody response against nucleocapsid and spike proteins of SARS-CoV-2 in 11 persons with mild or asymptomatic infection rapidly increased after infection. At weeks 18–30 after diagnosis, all remained seropositive but spike protein–targeting antibody titers declined. These data may be useful for vaccine development.

S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease (COVID-19) pandemic (1) . Effective vaccines are vital for mitigating the impact of the pandemic. As such, synthesizing a long-term humoral immune response to SARS-CoV-2 remains essential to developing and implementing a SARS-CoV-2 vaccine. We report a longitudinal study of 11 persons with SARS-CoV-2 infection in Vietnam, in which we monitored antibody responses for up to 30 weeks after infection.

We included patients with a confirmed SARS-CoV-2 infection admitted to a COVID-19 treatment center in central Vietnam during January-March 2020. To enable long-term follow-up, we excluded all short-term visitors. We collected information from each participant about clinical status, travel history, contacts with persons with confirmed cases, and personal demographics. For plasma collection, we applied a flexible sampling schedule encompassing 30 weeks after diagnosis, stratified by collection at 1, 2-3, 4-7, and ≥18 weeks after diagnosis.

We measured antibodies against 2 main immunogens of SARS-CoV-2, the nucleocapsid (N) and spike (S) proteins, by using 2 well-validated sensitive and specific serologic assays, Elecsys Anti-SARS-CoV-2 assay (Roche, https://diagnostics.roche.com) (2) and SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) (GenScript, https://www.genscript.com) (3). The former is an electrochemiluminescence immunoassay that uses recombinant N protein for qualitative detection of pan Ig, including IgG, against SARS-CoV-2. The latter is a surrogate assay for measuring receptor-binding domain-targeting neutralizing antibodies (RBD-targeting NAbs) (3, 4) , in principle a blocking ELISA that quantifies antibodies that block the receptor-RBD interaction (3). Our study forms part of the national COVID-19 response and was approved by the institutional review board of the Pasteur Institute in Nha Trang, Vietnam.

During the study period, there were a total of 23 patients with confirmed SARS-CoV-2 infection in central Vietnam. Ten were tourists and were thus excluded from the study. Of the remaining 13, a total of 11 consented to participate in this study. Among study participants, 6 were female and 5 were male; the age range was 12-64 years (Table) . Seven experienced mildly symptomatic infection and did not require supplemental oxygen during hospitalization; 4 were asymptomatic. Before becoming ill, 3 had traveled to a SARS-CoV-2-endemic country, including patients 2 and 3, who had traveled to Malaysia and patient 4 had traveled to the United States. Patient 4 transmitted the virus to 6 of her contacts, including 4 family members and 2 employees. Of these, 2 transmitted the virus to another family member ( 

Antibody response against nucleocapsid and spike proteins of SARS-CoV-2 in 11 persons with mild or asymptomatic infection rapidly increased after infection. At weeks 18-30 after diagnosis, all remained seropositive but spike protein-targeting antibody titers declined. These data may be useful for vaccine development. We collected 43 plasma samples from 11 participants within 4 time ranges after diagnosis: <1 week (n = 10), weeks 2-3 (n=11), weeks 4-7 (n=11), and weeks 18-30 (n = 11). During the first week after diagnosis, 1 patient (1/10, 10%) had detectable RBD-targeting NAbs, and none had antibodies against N protein.

In subsequent weeks, all (100%) participants tested positive by surrogate virus neutralization. Antibodies against N protein were detected in 10/11 (91%) of the samples collected between the second and third weeks after diagnosis and 11/11 (100%) samples collected at subsequent time points (Figure, panel A) .

Previous studies have demonstrated that the inhibition percentage measured by surrogate virus neutralization tests correlates well with neutralizing antibody titers measured by conventional virus neutralization assays or plaque-reduction neutralization tests (3, 4) . In our study, the inhibition percentage was below the assay cutoff in all but 1 plasma sample taken during the first week after diagnosis and then rapidly increased above the assay cutoff at subsequent time points. At weeks 18-30 after diagnosis, the inhibition percentage declined but remained detectable (Figure, panel B) .

We demonstrate that antibodies against 2 main structural proteins (S and N) of SARS-CoV-2 in patients with asymptomatic or mild infections were almost undetectable within the first week after diagnosis. Antibodies rapidly increased in subsequent weeks and peaked around weeks 4-7 before declining during the later phase of infection, consistent with previously reported findings (2, (5) (6) (7) . However, few studies have reported the persistence of long-term humoral immune response to SARS-CoV-2 up to 18-30 weeks after diagnosis (5), especially among mildly symptomatic or asymptomatic infected patients.

The titers of RBD-targeting NAbs, which are well correlated with those of neutralizing antibodies, decayed by weeks 18-30 after infection, suggesting that humoral immunity to SARS-CoV-2 infection may not be long lasting. Because neutralizing antibodies are recognized as a surrogate for protection (7) (8) (9) , followup studies beyond this period are needed to more conclusively determine the durability of these longterm responses and their correlation with protection.

Our collective findings offer insights into the long-term humoral immune response to SARS-CoV-2 infection. The data might have implications for COVID-19 vaccine development and implementation and other public health responses to the CO-VID-19 pandemic.

Antibody responses in 11 study participants, weeks 1-20 after PCR diagnosis of SARS-CoV-2 infection, Vietnam, 2020. A) Seroprevalence of SARS-CoV-2 among 11 COVID-19 patients. We followed testing protocols and the positive cutoff of 20% recommended in the Elecsys Anti-SARS-CoV-2 assay (Roche, https:// diagnostics.roche.com) without any modification. Using these parameters, previous studies showed an excellent concordance between results from surrogate virus neutralization tests and conventional neutralizing antibody detection assays (3, 4) . Vertical bars denote 95% CIs. Graphs were created using GraphPad Prism version 8.0 (GraphPad software, https://www.graphpad.com). B) Kinetics of neutralizing antibodies measured by the surrogate neutralization assay (GenScript, https://www.genscript.com) with the 20% cutoff applied. We tested samples at 1:10 dilution as specified. Because of the limited availability of plasma samples, each sample was tested only once. RBD, receptor-binding domain; NAbs, neutralizing monoclonal antibodies; S, spike; N, nucleocapsid. (COVID-19) , caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has not been fully assessed because most those infected have no or mild symptoms, and thus do not undergo viral nucleic acid or antigen testing (1-3). Determining the proportion of a population that has had infection at various time points is essential for understanding the dynamics of an epidemic in a particular area.

Puducherry district, population ≈1.25 million, is located in southern India. Its earliest recorded case of COVID-19 was in March 2020; it had 7 total cases by the end of May, 67 by end of June, and 663 by end of July 2020 (4). The district followed national CO-VID-19 management guidelines, including testing all symptomatic persons and their high-risk contacts.

We conducted 3 community-based serologic surveys for SARS-CoV-2 antibodies in Puducherry at 1-month intervals, i.e., during August 11-16, September 10-16, and October 12-16, 2020 (Figure) . Each survey included 900 adults selected using a multistage sampling procedure. In the initial stages, we chose 30 clusters, including 21 of 90 urban wards and 9 of 62 villages, using a probability proportional to size with replacement method; this method replicated the urban-to-rural ratio (70:30) of the district's population. Thereafter, in each cluster, we chose 30 households by systematic random sampling; we collected blood from 1 adult (>18 years of age) in each household using a modified Kish method (5, 6) . The data from these surveys represent the cumulative proportion of

Transmission of SARS-CoV-2 in domestic cats

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

The spectrum of pathological changes in severe acute respiratory syndrome (SARS)

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

for the China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera

Humoral immune response to SARS-CoV-2 in Iceland

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

on behalf of the Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Address for correspondence

We thank the patients for their participations in this study and the diagnostic team at the Hospital for Tropical Diseases, Le Nguyen Truc Nhu, Nguyen Thi Thu Hong for laboratory support. 

Ms. Mai is vice-head of the virology department of the Pasteur Institute in Nha Trang City, Vietnam. She has been part of a team responsible for COVID-19 diagnostics in an area of central Vietnam with a population of ≈25 million people.